Company intelligence / Profile preview

Molzym

Bremen, Bremen, Germanymolzym.com ↗

Ownership: Private
Development stage: Other

Overview

Molzym’s products are commercially available in over 30 countries. Their CE IVD-marked kits enable broad-range detection of bacteria and fungi directly from clinical samples using PCR or NGS methods. Clinical studies have demonstrated the ability to identify more than 1,300 species with high sensitivity, especially in samples negative by traditional culture due to prior antibiotic treatment.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic kitPCR-based assayNGS-based assay (Next Generation Sequencing)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Molzym.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molzym.

Explore the full profile